Using R2* values to evaluate brain tumours on magnetic resonance imaging: preliminary results.

Eur Radiol

The Department of Magnetic Resonance Imaging, Medical Image Center, the Second Affiliated Hospital of Nanchang University, 1, Minde Road, Donghu District, Nanchang, China, 330006,

Published: March 2014

Objective: To determine the usefulness of the R2* value in assessing the histopathological grade of glioma at magnetic resonance imaging and differentiating various brain tumours.

Methods: Sixty-four patients with brain tumours underwent R2* mapping and diffusion-weighted imaging examinations. ANOVA was performed to analyse R2* values among four groups of glioma and among high-grade gliomas (grades III and IV), low-grade gliomas (grades I and II), meningiomas, and brain metastasis. Spearman's correlation coefficients were used to determine the relationships between the R2* values or apparent diffusion coefficient (ADC) and the histopathological grade of gliomas. R2* values of low- and high-grade gliomas were analysed with the receiver-operator characteristic curve.

Results: R2* values were significantly different among high-grade gliomas, low-grade gliomas, meningiomas, and brain metastasis, but not between grade I and grade II or between grade III and grade IV. The R2* value (18.73) of high-grade gliomas provided a very high sensitivity and specificity for differentiating low-grade gliomas. A strong correlation existed between the R2* value and the pathological grade of gliomas.

Conclusions: R2* mapping is a useful sequence for determining grade of gliomas and in distinguishing benign from malignant tumours. R2* values are better than ADC for characterising gliomas.

Key Points: • Magnetic resonance imaging parameters are increasingly used to assess cerebral lesions. • R2* values are better than diffusion weighting for characterising gliomas. • R2* values can help distinguish among different grades of glioma. • Significant difference existed in R2* values between high- and low-grade gliomas.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-013-3057-xDOI Listing

Publication Analysis

Top Keywords

r2* values
36
high-grade gliomas
16
low-grade gliomas
16
r2*
14
magnetic resonance
12
resonance imaging
12
gliomas
11
brain tumours
8
grade
8
histopathological grade
8

Similar Publications

Background And Purpose: Degenerative cervical myelopathy (DCM) is the most common cause of spinal cord (SC) dysfunction. In routine clinical practice, SC changes are well depicted using conventional MRI, especially T2-weighted imaging. However, this modality usually fails to provide satisfactory clinico-radiological correlations.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Bernard and Irene Schwartz Center for Biomedical Imaging, New York University Grossman School of Medicine, New York, NY, USA.

Background: Amyloid related imaging abnormalities (ARIA), a group of neuropathological features seen in anti-amyloid immunotherapy patients, arises partly from CAA (Aβ buildup in blood vessels). Squirrel monkeys (SQMs), developing prominent age-related CAA exceeding brain Aβ, offer a unique NHP model for ARIA study. Evaluating edema-related neurobiological defects (ARIA-E) involves preferential use of T-weighted (T-w) and flow-attenuated inversion recovery (FLAIR) MRI while T*-weighted (T*-w) MRI is better suited for investigating iron-related pathology like microbleeds, hemorrhaging, and iron-homing in plaques.

View Article and Find Full Text PDF

Background: The 18F-AV-1451 radioligand enables in-vivo identification of tau neurofibrillary tangles that are considered as biomarkers of neurodegeneration in Alzheimer Disease (AD). However, off-target radioligand binding is also observed in basal ganglia, known as an iron-rich region. Hence, it is important to distinguish between radioligand-identified tissue neurodegeneration and iron-related radioligand binding effects.

View Article and Find Full Text PDF

Background: Given the increasing usage of plasma biomarkers for Alzheimer's disease (AD) studies, it is necessary to better understand relationships between plasma biomarker and PET and MR imaging outcomes, particularly within the AT(N) framework.

Method: We evaluated plasma samples from 233 subjects (age 74.05.

View Article and Find Full Text PDF

Background: Tau-PET tracers have been used to diagnose and stage Alzheimer's disease. However, different tau tracers present distinct patterns of binding throughout the brain, challenging the harmonization of their results. We hypothesize that the choice of a reference region can impact the harmonization of the tau-PET standardized uptake value ratio (SUVR).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!